Prostate cancer is one of the most frequently diagnosed malignant tumors in men. Despite significant advances in prevention and treatment, currently available therapeutic methods are not always fully effective, often leading to disease recurrence and metastasis to other organs. In cases of tumor progression, conventional treatments frequently prove insufficient. Modern radioligand therapies, such as the FDA-approved ¹⁷⁷Lu-PSMA-617 (Pluvicto®), demonstrate an efficacy of approximately 45%, with treatment resistance occurring in nearly 40% of patients. Therefore, there is an urgent need for novel, more effective targeted therapeutic approaches.
The presented project explores the use of ²²⁵Ac-PSMA I&T therapy as an innovative alternative for the treatment of prostate cancer.
BUDLEWSKI Tadeusz;
BRUCHERTSEIFER Frank;
MAJKOWSKA PILIP Agnieszka;
MORGENSTERN Alfred;
WALCZAK Rafal;
ITRYCH Bartosz;
WALECKI J;
2026-05-04
ELSEVIER INC.
JRC145578
1876-7982 (online),
https://www.sciencedirect.com/science/article/pii/S1939865426001074?via%3Dihub,
https://publications.jrc.ec.europa.eu/repository/handle/JRC145578,
10.1016/j.jmir.2026.102293 (online),
| Name | Country | City | Type |
|---|
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Datasets
| ID | Title | Public URL |
|---|
Dataset collections
| ID | Acronym | Title | Public URL |
|---|
Scripts / source codes
| Description | Public URL |
|---|
Additional supporting files
| File name | Description | File type |
|---|